Examiner-Initiated Interview Summary		
	10/582,887	MALYSKA ET AL.
	Examiner	Art Unit
	GAILENE R. GABEL	1641
All Participants:	Status of Application:	<u> </u>
(1) GAILENE R. GABEL.	(3)	
(2) <u>Catherine Gowen</u> .	(4)	
Date of Interview: 25 March 2010	Time:	
Type of Interview:  ☐ Telephonic ☐ Video Conference ☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)  Exhibit Shown or Demonstrated: ☐ Yes If Yes, provide a brief description:		
Part I.		
Rejection(s) discussed: of record.		
Claims discussed: of record.		
Prior art documents discussed: of record.		
Part II.  SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED: See Continuation Sheet		
Part III.		
It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability. It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.		
(A	pplicant/Applicant's Representat	ive Signature – if appropriate)

Application No.

Applicant(s)

Application No. 10/582,887

Continuation of Substance of Interview including description of the general nature of what was discussed: Indicated to Ms. Gowen that the working examples in the specification do not provide support or data excluding use of low ionic strength diluent solution (LISS) in admixture with the antigen positive RBCs to reduce time for agglutination formation in immunohematology testing in combination with the parameters of temperature, time, and continuous aggliation, as claimed. Suggested to Ms. Gowen to amend claim 1 to incorporate the LISS in admixture with the antigen positive RBCs. Ms. Gowen gave the Office authorization to amend claim 1 to recite, "antigen positive red blood cells admixed with low ionic strength diluent" and to cancel claims 8 and 10-24 in an Examiner's Amendment.